United Therapeutics (BSP:U2TH34) Long-Term Debt : R$0 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is United Therapeutics Long-Term Debt?

United Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2024 was R$0 Mil.

United Therapeutics's quarterly Long-Term Debt declined from Mar. 2024 (R$996 Mil) to Jun. 2024 (R$539 Mil) and declined from Jun. 2024 (R$539 Mil) to Sep. 2024 (R$0 Mil).

United Therapeutics's annual Long-Term Debt declined from Dec. 2021 (R$4,524 Mil) to Dec. 2022 (R$4,196 Mil) and declined from Dec. 2022 (R$4,196 Mil) to Dec. 2023 (R$1,470 Mil).

United Therapeutics Long-Term Debt Historical Data

The historical data trend for United Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Long-Term Debt Chart

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

2,462.70

4,115.76

4,523.92

4,196.32

1,469.94

United Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															2,469.35	1,469.94	995.96	538.61	-

United Therapeutics (BSP:U2TH34) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

United Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (BSP:U2TH34) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany UTH:Germany

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics Headlines

No Headlines